Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
The International Journal of Neuropsychopharmacology
|
November 29, 2024
Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression
Craig Chepke, Richard Shelton, Gerard Sanacora, et al.
Clinical Pharmacology and Therapeutics
|
August 30, 2020
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression
Eva G Katz, David Hough, Teodora Doherty, et al.
CNS Drugs
|
January 30, 2020
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Teodora Doherty, Ewa Wajs, Rama Melkote, et al.
The American Journal of Psychiatry
|
March 18, 2026
Comment on Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions
Muhammad Ahmed, Patricia Cabrera, Teodora Doherty, et al.
Psychotherapy and Psychosomatics
|
October 27, 2020
Comments to Drs. Gastaldon, Raschi, Kane, Barbui, and Schoretsanitis
Teodora Doherty, Ella J Daly, Janice Miller, et al.
Brain and Behavior
|
July 21, 2023
Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone
David M Kern, Carla M Canuso, Ella Daly, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
May 12, 2023
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
Naim Zaki, Li Nancy Chen, Rosanne Lane, et al.
The American Journal of Psychiatry
|
September 10, 2025
Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval
Gerard Sanacora, Muhammad Ahmed, Brianne Brown, et al.
The International Journal of Neuropsychopharmacology
|
May 4, 2025
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study
Naim Zaki, Li Nancy Chen, Rosanne Lane, et al.
The American Journal of Psychiatry
|
October 1, 2025
Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Carla M Canuso, Cynthia Bossie, Dong-Jing Fu, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
The International Journal of Neuropsychopharmacology
|
November 29, 2024
Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression
Craig Chepke, Richard Shelton, Gerard Sanacora, et al.
Clinical Pharmacology and Therapeutics
|
August 30, 2020
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression
Eva G Katz, David Hough, Teodora Doherty, et al.
CNS Drugs
|
January 30, 2020
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Teodora Doherty, Ewa Wajs, Rama Melkote, et al.
The American Journal of Psychiatry
|
March 18, 2026
Comment on Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions
Muhammad Ahmed, Patricia Cabrera, Teodora Doherty, et al.
Psychotherapy and Psychosomatics
|
October 27, 2020
Comments to Drs. Gastaldon, Raschi, Kane, Barbui, and Schoretsanitis
Teodora Doherty, Ella J Daly, Janice Miller, et al.
Brain and Behavior
|
July 21, 2023
Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone
David M Kern, Carla M Canuso, Ella Daly, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
May 12, 2023
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
Naim Zaki, Li Nancy Chen, Rosanne Lane, et al.
The American Journal of Psychiatry
|
September 10, 2025
Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval
Gerard Sanacora, Muhammad Ahmed, Brianne Brown, et al.
The International Journal of Neuropsychopharmacology
|
May 4, 2025
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study
Naim Zaki, Li Nancy Chen, Rosanne Lane, et al.
The American Journal of Psychiatry
|
October 1, 2025
Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Carla M Canuso, Cynthia Bossie, Dong-Jing Fu, et al.
Page
of 1